ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2020年01月30日 09時00分
Source:
Eisai
エーザイ、中国における新型コロナウイルス関連肺炎への対応活動支援について
東京, 2020年01月30日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、このたび、中華人民共和国(以下、中国)の湖北省武漢市を中心に感染が広がっている新型コロナウイルス関連肺炎について、現地での対応活動を支援するため、当社の中国子会社を通じて、非営利団体である武漢市慈善総会(武汉市慈善总会)に100万元(日本円で約1600万円)の義援金を寄付することを決定しました。また、現地の医療機関に対して、医薬品の提供を行います。
中国における新型コロナウイルス関連肺炎患者様の早期回復と感染の終息を心より祈念いたします。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2020/news202007.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Hitachi Advances Strategic Alliance with Google Cloud to Empower Frontline Workers with Field-Specific AI Agents
Oct 11, 2025 00:58 JST
Honda Issues Integrated Report - "Honda Report 2025"
Oct 11, 2025 00:46 JST
DENSO's Electrification Products Adopted for TOYOTA's New "bZ4X"
Oct 11, 2025 00:21 JST
Newly developed eAxle adopted for TOYOTA's new "bZ4X"
Oct 11, 2025 00:08 JST
MHIET and MHI-TC Complete Delivery of First "COORDY" Controller Providing Optimized Control of Multiple Power Sources
Oct 10, 2025 23:47 JST
Fujitsu migrates service operations virtualization platform used by 3,000 companies to Nutanix and introduces migration support services utilizing proven expertise
Oct 10, 2025 23:25 JST
Anime Tokyo Station: TV Anime 'SPYxFAMILY' Special Exhibition, New Designs Added for Admission Bonus Illustration Cards
Oct 10, 2025 11:30 JST
TANAKA to Provide Medals Expressing Every Runner's Trail through Flowing Curves for the Tokyo Legacy Half Marathon 2025
Oct 10, 2025 03:00 JST
Genequest and Fujitsu uncover new insights into genetics-lifestyle relationships through high-speed, reliable causal AI from Fujitsu Kozuchi
Oct 10, 2025 00:55 JST
Sharp Launches A3 MFPs (BP Series)
Oct 10, 2025 00:50 JST
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony in Shimonoseki for Large Car Ferry HAMANASU
Oct 10, 2025 00:42 JST
Honda Celebrates 30th Anniversary of CR-V
Oct 09, 2025 23:54 JST
DASSAI MOON Project, the World's First Test Brewing of Sake in Space
Oct 09, 2025 23:23 JST
All-New Destinator Wins Gold Award at VMARK Vietnam Design Award 2025
Oct 09, 2025 22:17 JST
Mazda Tests Feasibility of Commercializing Corrosion Resistance Evaluation Service for Coated Components
Oct 09, 2025 21:29 JST
Sumitomo Metal Mining and Toyota Collaborate on Mass Production of Cathode Materials for All-Solid-State Batteries
Oct 09, 2025 20:40 JST
Fujitsu and ARYA develop high-precision AI solution for instant detection of suspicious behavior
Oct 08, 2025 14:39 JST
Toda, JTB and Fujitsu kick off NFT-powered digital transformation project to boost international tourism to Japan
Oct 08, 2025 13:39 JST
Fujitsu and Sony Bank partner to integrate generative AI into core banking system design and development
Oct 08, 2025 13:02 JST
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
Oct 08, 2025 12:03 JST
More Latest Release >>
Related Release
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
10/8/2025 12:03:00 PM JST
Eisai Highlights Breadth of Oncology Research at ESMO 2025
10/3/2025 6:01:00 PM JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
9/29/2025 10:33:00 AM JST
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
9/24/2025 7:04:00 PM JST
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
9/17/2025 6:20:00 PM JST
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
9/12/2025 1:20:00 PM JST
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
9/8/2025 5:49:00 PM JST
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
9/4/2025 10:56:00 AM JST
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
9/3/2025 11:32:00 AM JST
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
9/1/2025 1:44:00 PM JST
More Press release >>